Department of General Pediatrics, Neonatology, and Pediatric Cardiology, University Children's Hospital Düsseldorf, Düsseldorf, Germany.
J Pediatr. 2013 Dec;163(6):1728-1732.e1. doi: 10.1016/j.jpeds.2013.07.014. Epub 2013 Aug 22.
To evaluate acceptability of 2 mm solid dosage forms (mini-tablets) as an alternative administration modality in young children in comparison with syrup.
Three hundred six pediatric in- and outpatients aged 6 months-5 years (51 in each of 6 age groups) were recruited. An open, randomized cross-over study was conducted to compare acceptability and capability to swallow 2 mm uncoated or coated mini-tablets vs 3 mL syrup.
In the overall patient population of 306 children, the acceptability of uncoated mini-tablets was superior to syrup (difference in proportions 14.8%, 95% CI 10.2-19.4; P < .0001). In line with this finding, the level of capability to swallow was higher for uncoated mini-tablets compared with syrup as well (difference in proportions 12.3%, 95% CI 5.4-19.3; P = .0008). All 3 pharmaceutical formulations were well tolerated, and none of the 306 children inhaled or coughed because of the syrup or the uncoated mini-tablet; only 2 of the 306 children (both in age group 0.5-1 year) coughed because of the coated mini-tablet, in both cases without clinical relevance.
Mini-tablets are a valuable alternative to syrup for children 6 months-6 years of age and are more acceptable compared with liquid formulation. Regulatory bodies such as Food and Drug Administration and European Medicine Agency are encouraged to take our data into account for guideline updates and future drug approval processes.
评估 2 毫米固体制剂(迷你片剂)作为替代管理方式在幼儿中的可接受性,与糖浆相比。
招募了 306 名 6 个月至 5 岁的儿科门诊和住院患者(每个年龄组 51 名)。进行了一项开放、随机交叉研究,以比较 2 毫米未包衣或包衣迷你片剂与 3 毫升糖浆的可接受性和吞咽能力。
在 306 名患儿的总体患者人群中,未包衣迷你片剂的可接受性优于糖浆(比例差异 14.8%,95%置信区间 10.2-19.4;P<.0001)。与这一发现一致,未包衣迷你片剂的吞咽能力也高于糖浆(比例差异 12.3%,95%置信区间 5.4-19.3;P=0.0008)。所有 3 种药物制剂均耐受良好,306 名儿童中没有因糖浆或未包衣迷你片剂而吸入或咳嗽的情况;只有 306 名儿童中的 2 名(均在 0.5-1 岁年龄组)因包衣迷你片剂咳嗽,但均无临床相关性。
迷你片剂是 6 个月至 6 岁儿童的一种有价值的糖浆替代品,与液体制剂相比更具可接受性。鼓励食品和药物管理局和欧洲药品管理局等监管机构考虑我们的数据,以更新指南和未来的药物批准程序。